Figure 7.

Targeted alpha therapy with the ²²⁵Ac-TM in a xenograft mouse model of PCa. (A,B) Individual or (C,D) averaged curves for (A,C) the tumor volume, and (B,D) body weight changes after DOTAGA-TM (control, n = 4) or ²²⁵Ac-TM (n = 5) injection in tumor-bearing mice. (E) The SGR of the relative tumor volumes were calculated with the exponential growth equation. SGR values for tumors of the control (0.0558 ± 0.0025, n = 4) and treatment group (0.0217 ± 0.0052, n = 5) correspond to doubling times of 12.4 and 32.0 days, respectively. Data are presented as means ± SEM. For each time point, the SGR of the single animals was analyzed with an unpaired t-test without assumption of consistent SD; the calculations were corrected for multiple comparisons using Holm-Sidak method; alpha of 0.05 was defined as ‘statistically significant’.